Born: 1966
Title: Chief Medical Officer
Education: PhD, MD and specialist degree in oncology at Karolinska Institute/University hospital.
Employed: 2023
Background: Pia Baumann has substantial experience in drug development in the cancer field. Her experience comes from many years of clinical work at Karolinska Hospital and larger pharmaceutical companies as well as smaller biotech companies. Pia has developed global product strategies as well as designed and conducted clinical studies in close collaboration with leading clinics. Former Vice President Medical at AstraZeneca. Prior to that leading, global positions in cancer drug development at Takeda, Incyte and ARIAD Pharmaceuticals.
Shares in Medivir: 96,000 ordinary shares.
Warrants in Medivir: 0.
Born: 1974
Title: Chief Financial Officer.
Education: Degree of Bachelor of Science in Accounting and Finance.
Employed: 2019
Background: Over 20 years of experience in finance. Interim CEO at Medivir, May 2021-January 2022. Former CFO at O'Learys Trademark AB. Prior to that, Interim CFO at Rebtel and Head of Business Control at ICA Sverige AB. Before that held leading positions at Scan AB and SkiStar AB. Experience of working in listed-, private equity- and private companies.
Shares in Medivir: 238,000 ordinary shares.
Warrants in Medivir: 150,000
Born: 1971
Title: Chief Executive Officer
Education: Bachelor of Science in Business Administration
Employed: 2022
Background: 25 years of experience from pharmaceutical industry spanning global and local responsibilities. Has led product strategy development for late stage compounds preparing for regulatory approval and commercialisation as well as execution of launch for multiple compounds in specialty care. Primary area of focus in the past 10 years in the field of Oncology. Experience also includes interim CEO role for Sedana Medical AB and Director Investor Relations at AstraZeneca.
Chairman of the Board of Braincool AB.
Shares in Medivir: 668,000 ordinary shares.
Warrants in Medivir: 250,000.
Born: 1965
Title: Chief Scientific Officer
Education: PhD in Medical Science at Uppsala University
Employed: 2011
Background: More than 25 years of experience in cancer research. During the last 10 years focused on industrial drug discovery and development projects in oncology. Prior to that he managed an academic research group as principal investigator, and has initiated several innovative scientific projects in cancer biology. He has published more than 50 scientific articles and holds several patents. Adjunct professor at the Medical Faculty of Uppsala University.
Shares in Medivir: 123,908 ordinary shares
Warrants in Medivir: 100,000